AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16448552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (1.5-6 g daily, orally t.i.d.)
Number of subjects: 20
Study 15303786 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent with occlusion (bioceramic-coated neoprene garment)
Number of subjects: 20
Study 15303786 — intervention group
Group type: COMPARATOR
Intervention: Topical agent without occlusion
Number of subjects: 20
Study 11550168 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing educational print materials
Number of subjects: 391
Study 11550168 — intervention group
Group type: COMPARATOR
Intervention: General breast cancer education control materials
Number of subjects: 391
Study 9257414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin D3 administration
Number of subjects: 0
Study 8218671 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg orally every 12 hours
Number of subjects: 42
Study 8218671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8218671 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMZ
Number of subjects: 42
Study 3497990 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine (two doses, separated by two months)
Number of subjects: 100
Study 3497990 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 3497990 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 100
Study 30395145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message with anger emotion induction (mothers)
Number of subjects: 190
Study 30395145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message with anger emotion induction (fathers)
Number of subjects: 190
Study 30395145 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message (not specified if anger or fear)
Number of subjects: 190
Study 30395145 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed message with fear emotion induction (not specified if mothers or fathers)
Number of subjects: 190
Study 30395145 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed message with fear emotion induction (not specified if mothers or fathers)
Number of subjects: 190
Study 30058824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness induction (body scan)
Number of subjects: 53
Study 30058824 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 53
Study 27627981 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 52
Study 27627981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 52
Study 27627981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 27627981 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide and Sitagliptin
Number of subjects: 52
Study 23959713 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific computerized training (ST), n=55
Number of subjects: 88
Study 23959713 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific computerized training (n-ST), n=33
Number of subjects: 88
Study 23964461 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror neurons stimulation based VCD program practice at home
Number of subjects: 30
Study 23964461 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 30
Study 20569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment with adjunctive dose of vitamin C (ChP1)
Number of subjects: 60
Study 20569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment alone (ChP2)
Number of subjects: 60
Study 20569170 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 60
Study 20569170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive vitamin C
Number of subjects: 60
Study 17711908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide (CYC), calcineurine inhibitors (cyclosporine or tacrolimus), mycophenolate mofetil, azathioprine, rituximab
Number of subjects: 0
Study 17711908 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment regimens including high doses of cyclophosphamide (CYC) and steroids
Number of subjects: 0
Study 15289700 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/day
Number of subjects: 192
Study 15289700 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day
Number of subjects: 192
Study 15289700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 11379805 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg/day
Number of subjects: 138
Study 11379805 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate 60 mg/day
Number of subjects: 138
Study 9225837 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (2 IU/m2) for 12 months
Number of subjects: 27
Study 9225837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7968874 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once daily
Number of subjects: 49
Study 3301500 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (V) 240 mg/die
Number of subjects: 54
Study 3301500 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (C) 50 mg/die
Number of subjects: 54
Study 3301500 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (V) 240 mg/die + Chlorthalidone (C) 50 mg/die (V + C)
Number of subjects: 54
Study 28851063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT, n = 10)
Number of subjects: 28
Study 28851063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness program (MF, n = 9)
Number of subjects: 28
Study 28851063 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 28
Study 27770114 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with 200mcg of phenylephrine
Number of subjects: 72
Study 27770114 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with 100mcg of phenylephrine
Number of subjects: 72
Study 27770114 — intervention group
Group type: COMPARATOR
Intervention: Propofol mixed with normal saline
Number of subjects: 72
Study 24822236 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated appliance (Relax)
Number of subjects: 48
Study 24822236 — intervention group
Group type: COMPARATOR
Intervention: Stabilization appliance
Number of subjects: 48
Study 24822236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 22116817 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) by 3 cycles of 5 minutes of arm ischemia/5 minutes of reperfusion
Number of subjects: 24
Study 22116817 — intervention group
Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 24
Study 22116817 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 24
Study 20858400 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost/timolol fixed combination
Number of subjects: 20
Study 20858400 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 18499789 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (CE-MRA)
Number of subjects: 44
Study 18499789 — intervention group
Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 44
Study 18499789 — intervention group
Group type: EXPERIMENTAL
Intervention: Body remnants characterized by remnant protrusion into the coil mass
Number of subjects: 44
Study 16641657 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in decision-making (IDM) rated on a 5-point scale
Number of subjects: 0
Study 12562448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet, 15 mg
Number of subjects: 120
Study 12562448 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet, 30 mg
Number of subjects: 120
Study 12562448 — intervention group
Group type: COMPARATOR
Intervention: Intact capsule formulation of lansoprazole
Number of subjects: 120
Study 11253476 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic speech analysis in ALS patients
Number of subjects: 77
Study 8637408 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine (30, 75, 150, 225 mg/day for one week)
Number of subjects: 236
Study 8637408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study 8637408 — intervention group
Group type: EXPERIMENTAL
Intervention: Velnacrine
Number of subjects: 236
Study 1350927 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetorphan (100 mg t.d.s.)
Number of subjects: 12
Study 1350927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6529914 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg Ro 21-5521 per day
Number of subjects: 12
Study 6529914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30904178 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine 80/10 mg + Rosuvastatin 20 mg (TAR group)
Number of subjects: 134
Study 30904178 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine 80/10 mg (TA group)
Number of subjects: 134
Study 30904178 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + Rosuvastatin 20 mg (TR group)
Number of subjects: 134
Study 30904178 — intervention group
Group type: COMPARATOR
Intervention: Control group (TA and TR)
Number of subjects: 134
Study 29774562 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple, low-cost group-counselling programme
Number of subjects: 769
Study 29774562 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 769
Study 27094109 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study 24184810 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks
Number of subjects: 462
Study 24184810 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus PegIFN and RBV for 48 weeks
Number of subjects: 462
Study 24184810 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (100 or 150 mg, once daily)
Number of subjects: 462
Study 24184810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 22266898 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL mepivacaine 1.5%
Number of subjects: 30
Study 22266898 — intervention group
Group type: COMPARATOR
Intervention: 40 mL mepivacaine 1.5%
Number of subjects: 30
Study 21148134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting intervention (gym membership and 13 weeks of supervised instruction, followed by 9 months unsupervised)
Number of subjects: 154
Study 21148134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 154
Study 21148134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting intervention (among women with 5 or more lymph nodes removed)
Number of subjects: 154
Study 21148134 — intervention group
Group type: COMPARATOR
Intervention: Control group (among women with 5 or more lymph nodes removed)
Number of subjects: 154
Study 21148134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting intervention
Number of subjects: 154
Study 21148134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 17937368 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 47
Study 17937368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12656547 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line catheter suction system
Number of subjects: 14
Study 12656547 — intervention group
Group type: COMPARATOR
Intervention: Open catheter suction
Number of subjects: 14
Study 10901509 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg daily)
Number of subjects: 16
Study 10901509 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy (0.625 mg conjugated oestrogen and 2.5 mg medroxyprogesterone acetate daily)
Number of subjects: 16
Study 10901509 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (simvastatin + hormone replacement therapy)
Number of subjects: 16
Study 10901509 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16
Study 8622055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimen (one cycle of MOPP monthly alternated with one cycle of ABVD)
Number of subjects: 427
Study 8622055 — intervention group
Group type: COMPARATOR
Intervention: Hybrid regimen (one-half cycle of MOPP alternated with one-half cycle of ABVD within a 1-month period)
Number of subjects: 427
Study 8622055 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating regimen
Number of subjects: 427
Study 8622055 — intervention group
Group type: COMPARATOR
Intervention: Hybrid regimen
Number of subjects: 427
Study 8622055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 427
Study 1358118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40
Study 1358118 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study 6367362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (800-2800 mg/day, median 1600 mg/day)
Number of subjects: 16
Study 6367362 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (6-18 mg/day, median 12 mg/day)
Number of subjects: 16
Study 31465088 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus aflibercept (4 mg/kg every 2 weeks for 6 cycles, 3 months)
Number of subjects: 180
Study 31465088 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 without aflibercept
Number of subjects: 180
Study 31465088 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus aflibercept
Number of subjects: 180
Study 28573377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored patient activation DXA result letter and bone health brochure
Number of subjects: 7749
Study 28573377 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no tailored letter or brochure)
Number of subjects: 7749
Study 25788199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) for 5 years
Number of subjects: 348
Study 25788199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) for 5 years in HBeAg-positive patients
Number of subjects: 348
Study 23122916 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW (0.25 mA current, 130 μs pulse width)
Number of subjects: 331
Study 23122916 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDIUM (0.5-1.0 mA, 250 μs)
Number of subjects: 331
Study 23122916 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (1.25-1.5 mA, 250 μs)
Number of subjects: 331
Study 23122916 — intervention group
Group type: EXPERIMENTAL
Intervention: VNS therapy (all doses)
Number of subjects: 331
Study 22194125 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 54
Study 22194125 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 54
Study 19351753 — intervention group
Group type: EXPERIMENTAL
Intervention: G3139
Number of subjects: 0
Study 17097772 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone + Phenylbutyrate
Number of subjects: 7
Study 17595600 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking recovery rehabilitation program with specific back exercises
Number of subjects: 37
Study 17595600 — intervention group
Group type: COMPARATOR
Intervention: Walking recovery rehabilitation program without specific back exercises (control group)
Number of subjects: 37
Study 11450082 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for spontaneous supratentorial intracerebral haemorrhage
Number of subjects: 0
Study 11450082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 0
Study 8783326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular clonidine 150 micrograms diluted in 20 ml of isotonic saline
Number of subjects: 40
Study 8783326 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1 mg diluted in 20 ml of isotonic saline injected into the knee joint
Number of subjects: 40
Study 8783326 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular isotonic saline
Number of subjects: 40
Study 8783326 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular isotonic saline and subcutaneous clonidine 150 micrograms
Number of subjects: 40
Study 1740587 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscarinic stimulation by methacholine
Number of subjects: 0
Study 1740587 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 1740587 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (alpha-adrenergic agonist)
Number of subjects: 0
Study 1740587 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic agonists
Number of subjects: 0
Study 6711670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening test using consonant‐vowel dichotic stimuli
Number of subjects: 90
Study 30678199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1200 IU vitamin D₃ per day)
Number of subjects: 131
Study 30678199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 29920116 — intervention group
Group type: EXPERIMENTAL
Intervention: molindone
Number of subjects: 119
Study 29920116 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 119
Study 29920116 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 119
Study 27127102 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine (Val/Aml 80/5 mg) single-pill combination for 8 weeks
Number of subjects: 11312
Study 25458200 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (400 mg, twice daily)
Number of subjects: 86
Study 25458200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 22904136 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent CIN 3 cases diagnosed within 2 years
Number of subjects: 613
Study 22904136 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident CIN 3 cases diagnosed following an incident HPV infection
Number of subjects: 613
Study 20399059 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (target dose, 2000 mg/day)
Number of subjects: 315
Study 20399059 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 315
Study 18700693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg)
Number of subjects: 37
Study 18700693 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 37
Study 18700693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15800995 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV pre-core mutant group
Number of subjects: 140
Study 15800995 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV pre-core wild-type group
Number of subjects: 140
Study 15800995 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 140
Study 12876093 — intervention group
Group type: COMPARATOR
Intervention: Diet very low in saturated fat (control group)
Number of subjects: 46
Study 12876093 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin, 20 mg/d
Number of subjects: 46
Study 12876093 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in plant sterols, soy protein, viscous fibers, and almonds (dietary portfolio)
Number of subjects: 46
Study 10447643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3% eye drops twice daily (LF)
Number of subjects: 582
Study 10447643 — intervention group
Group type: COMPARATOR
Intervention: Control antibiotics (combined control group, CCG)
Number of subjects: 582
Study 8681494 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat (0.5 to 1.0 mg, 1.0 to 2.5 mg, 5.0 to 10.0 mg)
Number of subjects: 0
Study 8681494 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat (multiple doses every 6 hours on days 2 and 3)
Number of subjects: 0
Study 8681494 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 0
Study 8681494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2071560 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral physostigmine administered four times daily for 3 weeks
Number of subjects: 8
Study 2071560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31776012 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 55
Study 31776012 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective local anaesthetic (SNT)
Number of subjects: 55
Study 31776012 — intervention group
Group type: COMPARATOR
Intervention: Control group (Corticosteroids)
Number of subjects: 55
Study 31776012 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 31862738 — intervention group
Group type: EXPERIMENTAL
Intervention: HH intervention including interactive simulation learning, educational emails, and education and poster reminders from WHO and Global Handwashing Day website.
Number of subjects: 70
Study 31862738 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 70
Study 27806997 — intervention group
Group type: EXPERIMENTAL
Intervention: BokSmart Safe Six exercise intervention in warm-up
Number of subjects: 0
Study 27806997 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual warm-up)
Number of subjects: 0
Study 27806997 — intervention group
Group type: EXPERIMENTAL
Intervention: BokSmart Safe Six exercise intervention
Number of subjects: 0
Study 26138292 — intervention group
Group type: EXPERIMENTAL
Intervention: Enforced expression of Bcl-3 in CD4+ T cells
Number of subjects: 0
Study 26138292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bcl-3 silencing in CD4+ T cells
Number of subjects: 0
Study 26138292 — intervention group
Group type: EXPERIMENTAL
Intervention: Bcl-3 levels in CD4+ T cells from RA patients
Number of subjects: 0